There has been a remarkable explosion in medical information over the past several years. The rate of new discoveries and improved understanding of the biology and treatment of cancer is ever-increasing. The same is true in the area of supportive cancer therapy. [1] There has been a remarkable explosion in medical information over the past several years. 
patients hospitalized ≥ 10 days accounted for 74% of hospital days and 78% of total cost. Over the 6 years of observation, LOS decreased 10% while cost per day and total cost increased 28% and 13%, respectively. Documented infection was reported in 38% of patients including sepsis in 19% and pneumonia in 10%. Death during hospitalization was reported in 11% of admissions. Mortality was most commonly associated with gram-negative sepsis (34%), pneumonia (27%), or comorbidities including renal (30%), cerebrovascular (30%), liver (28%), and lung disease (27%). Mortality rates increased with the number of comorbidities (P trend < .001). Odds ratios for death were as follows: gramnegative sepsis (4.8), pneumonia (2.4), renal (3.1), cerebrovascular (3.2), liver (2.9), and lung disease (3.9). Odds ratios for complicated hospitalization (length of stay ≥ 10 days) were leukemia (3.4), grampositive sepsis (2.5), and comorbidities with lung (2.1), renal (2.1), cerebrovascular (2.1), and liver disease (2.0) after adjustment for other comorbidities and infectious complications. CONCLUSION: Hospitalization for FN is associated with considerable morbidity and mortality. Numerous patient characteristics, comorbidities, and infectious complications are associated with increased mortality, length of stay, and cost. Febrile neutropenia (FN), the major dose-limiting toxicity of cancer chemotherapy, frequently requires hospitalization for the administration of empiric broad spectrum antibiotics. For a better understanding of the clinical impact and economics of hospitalization for FN, the records of 41,779 adult nontransplant cancer patients admitted with FN at 115 academic medical centers between 1995 and 2000 were analyzed using the discharge database of the University HealthSystem Consortium. Primary outcomes included length of stay (LOS), cost, infectious complications, and mortality. Average age was 53.6 years with 28% ≥ 65 years. Mean (median) LOS was 11.2 (6) days while the average (median) cost was $19,110 ($8,376) per episode. The 35% of patients hospitalized for ≥ 10 days accounted for 74% of hospital days and 78% of total cost. Documented infection and death during hospitalization were reported in 38% of patients and 11% of admissions, respectively. Mortality rates increased with the number of comorbidities (P-trend < .0001). In multivariate analysis, risk factors (odds ratios) for inpatient mortality were gram-negative sepsis (4.84), pneumonia (2.33), and renal (3.19), cerebrovascular (3.29), liver (2.93), and lung disease (3.95); predictors for LOS ≥ 10 days were grampositive sepsis (2.39), leukemia (3.54), and various comorbidities. Risk scores for LOS ≥ 10 days (range: 0-32) and inpatient mortality (range: 0-34) were derived from the logistic regression models. These risk scores effectively discriminated patients at high risk for prolonged hospitalization with FN and inpatient mortality. The 24% of patients with risk scores > 4 experienced a risk of ≥ 50% for LOS ≥ 10 days. Similarly, the 27% of patients with risk Page 
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Published on Physicians Practice (http://www.physicianspractice.com) scores > 5 experienced a risk of ≥ 12% for inpatient mortality. CONCLUSION: By identifying individual cancer patients at increased risk for prolonged hospitalization and inpatient mortality, the risk score analysis may help guide supportive care treatment decisions, improve outcomes, and potentially reduce the cost of cancer care. The purpose of this study was to evaluate human resource costs and patient time associated with the delivery of chemotherapy and management of chemotherapy-induced neutropenia (CIN). A total of 400 medical professionals were surveyed regarding human resource time associated with medical tasks, and 189 patients were surveyed regarding time and activities affected by medical visits across 20 community oncology practices. Results [mean (standard deviation)] showed chemotherapy and CIN-related medical visits involve numerous types of professionals (X = 10 per practice) who execute multiple medical tasks (X = 230 per practice), resulting in substantial human resource time and expense to the practice. For example, 1 day of chemotherapy X = 4.23 (1.48) hours, $152.55 ($65.89); midcycle lab visit X = 2.09 (1.05) hours, $48.62 ($28.22); 5 days of IV antibiotics X = 15.7 (6.1) hours, $415.9 ($213.6); 10 days of filgrastim X = 24.4 (11.1) hours, $579.30 ($292.60); 1 day of pegfilgrastim X = 2.40 (1.12) hours, $57.06 ($30.94). Furthermore, results showed that even relatively simple medical visits resulted in large disruptions of patient time and life activities before, during, and after the visit. For example, 1 day of chemotherapy X = 8.19 (3.93) hours; midcycle lab visit X = 2.27 (0.92) hours; 5 days of IV antibiotics X = 16.31 (4.92) hours; 10 days of filgrastim X = 23.2 (9.01) hours; 1 day of pegfilgrastim X = 2.36 (1.44) hours. Sensitivity analysis demonstrated that as rates of severe CIN increase, human resource costs and patient burden increase. At relatively high rates of CIN, prophylactic use of growth factors was predicted to be less burdensome to patients and more cost-effective in terms of human resource costs. CONCLUSION: These data are important for understanding the cost implications of delivering chemotherapy in the community oncology setting. These data are also important for understanding the burden multiple medical visits place on patients and their caregivers and may help guide the creation of supportive care strategies that minimize unnecessary patient and caregiver burden. (FN) is a major complication of chemotherapy in patients with small-cell lung cancer (SCLC). Granulocyte colony-stimulating factor (G-CSF) is used to prevent FN, but its primary use is only recommended in patients with a considerable (> 40%) risk of FN (ASCO guidelines, J Clin Oncol 2000). Antibiotics are also effective in preventing FN, even reduce infection-related mortality, and are cost-effective (Tjan-Heijnen VC: Ann Oncol 2001). In this multicenter randomized phase III trial, the role of combined primary prophylaxis with antibiotics plus G-CSF in patients with SCLC at increased risk of FN was determined. Patients with SCLClimited disease and performance status (PS) 2/3, or age over 60 years or judged not suitable for concurrent chemo/radiotherapy, and patients with SCLCextensive disease were considered at increased risk of FN. Patients were stratified for age (< / ≥ 60 years), PS (0-1/2), extent of disease (limited/extensive), and line of therapy (first/second), and randomized for primary prophylaxis with antibiotics (ciprofloxacin 500 mg + roxithromycin 150 mg, bid, days 4-13) alone or in combination with G-CSF (filgrastim 5 μg/ kg/d, days 4-13). Chemotherapy consisted of cyclophosphamide 1,000 mg/m Table 1 for results. A total of 171 patients were eligible. Patient characteristics were well balanced.
CONCLUSION: The addition of primary prophylactic G-CSF to prophylactic antibiotics significantly reduced the incidence of chemotherapy-related FN in SCLC patients at increased risk of FN, especially in the first cycle by 50%. Abstract #620 43). In our study of TAC vs FAC for node-negative breast cancer, we performed an interim safety analysis to assess the impact of growth factor support on the incidence of TAC-related adverse events. Following surgery, patients with operable, highrisk (St Gallen, 1998 Current treatment guidelines recommend prophylactic use of colony-stimulating factors for treatment regimens associated with a ≥ 40% incidence of FN. To test whether patients at moderate risk of FN may also benefit from once-per-cycle. first-cycle use of pegfilgrastim, this phase III randomized, doubleblind, placebo-controlled study evaluated the effects of prophylactic, fixed doses of pegfilgrastim on the incidence of FN in patients with breast cancer receiving docetaxel; which is associated with an average reported FN incidence of 20% in the absence of growth factor support.
Patients with breast cancer (stage II to IV) and an ECOG performance status of 0 to 2 who were candidates for docetaxel chemotherapy (100 mg/m 2 every 3 weeks) were eligible for participation.
Patients were randomized in a 1:1 allocation to receive either 6 mg of pegfilgrastim or placebo once per cycle on the day after docetaxel administration for up to four cycles. Febrile neutropenia was defined as a temperature ≥ 38. , with 1,480 evaluable for safety (TAC 744, FAC 736) . A similar number of cycles were delivered in both arms (TAC 4010, FAC 4007 
then focused attention on all patient-cycles in which G-CSF was administered on or before cycle day 5 ("G-CSF prophylaxis"). Pooling all such cycles, we used a Generalized Estimating Equation (GEE) model (with a logistic link function) to examine the relationship between duration of G-CSF prophylaxis and risk of hospitalization for neutropenia or infection and risk of hospitalization for any reason, controlling for potential confounders. Mean (SD) duration of G-CSF prophylaxis was
showed that dose-dense ACE (doxorubicin [Adriamycin], cyclophosphamide, etoposide) with G-CSF allows delivery of "chemotherapy planned dose on time" (CPDOT), leading to improved survival in subjects with extensive small-cell lung cancer (SCLC). The aim of this study was to show that pegfilgrastim can also support ACE 14 CPDOT in this setting
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Published on Physicians Practice (http://www.physicianspractice.com) were more frequent in the dose-intensified group of older patients (6% in A1 vs 17% in A2; 6% in B1 vs 11% in B2). The hematologic toxicity data are shown in Table 1 . NCI-CTC grade 3/4 nonhematologic toxicities were rare and revealed no differences between the groups.
CONCLUSION:
The administration of a dosedense regimen with epirubicin and paclitaxel followed by CMF with G-CSF support is feasible in elderly patients with a tolerable safety profile. Referring to the analyzed data, a decreased hematopoietic potency must be considered in older patients. 3 ) or febrile neutropenia, which often results in fever, infection, and hospitalization. This can lead to dose delays or reductions in subsequent chemotherapy cycles and/or early termination of therapy. Recent studies suggest most patients who experience severe febrile neutropenia do so early in the course of chemotherapy, in particular during the first cycle. Several recent risk models for neutropenia have identified baseline patient characteristics that predict the occurrence of neutropenia. The ability to identify patients at risk for developing neutropenia early in their therapy might help guide appropriate hematopoietic growth factor use. We evaluated possible risk factors associated with cycle 1 severe febrile neutropenia among a sample of patients with non-Hodgkin's lymphoma (NHL) or breast cancer. A historical case series of 1,617 patients (704 NHL and 913 early-stage breast cancer) who received initial chemotherapy at 16 community and academic oncology practices between 1991 and 1999 were selected for study. Severe febrile neutropenia was defined as an absolute neutrophil count ≤ 250/mm 3 or febrile neutropenia. A total of 461 patients (29%) experienced at least one episode of severe febrile neutropenia; 268 (58%) of these patients (167 [59%] with NHL and 101 [56%] with breast cancer) had severe febrile neutropenia in cycle 1. Risk factors associated with cycle 1 severe febrile neutropenia included age ≥ 65 years (odds ratio [OR] 2.08; 95% CI = 1.48-2.92); baseline hemoglobin < 12.0 g/dL (OR 1.90; 95% CI = 1.41-2.58); presence of heart, renal, or liver disease (OR 2.12; 95% CI = 1.03-4.36); NHL (OR 1.64; 95% CI = 1.16-2.32); planned full chemotherapy dose intensity (OR 2.74; 95% CI = 1.55-4.84); and no growth factor in the first 5 days of cycle 1 (OR 1.82; 95% CI = 1.07-3.08). CONCLUSION: Data routinely available to the clinician can help identify patients at risk for severe febrile neutropenia in cycle 1. In our model assessing chemotherapy-related severe febrile neutropenia in breast cancer and lymphoma, patients ≥ 65 were twice as likely to have severe febrile neutropenia in cycle 1. Abstract #A-60
